Clear Street analyst Bill Maughan initiated coverage of Cellectis (CLLS) with a Buy rating and $9 price target Cellectis has produced “strong” efficacy data from its initial program, lasme-cel in acute lymphoblastic leukemia, and “an encouraging initial efficacy signal” from eti-cel in non-hodgkin’s lymphoma, which the firm believes positions Cellectis well to be among the first companies to bring an allogenic CAR-T product for the treatment of hematological cancers to market.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS:
- Cellectis Announces Arbitral Decision in Servier Dispute
- Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
- Cellectis announces arbitral decision in dispute with Servier
- Cellectis Unveils Promising Phase 1 Results for Eti-cel at ASH 2025
- Cellectis S.A. Updates Patent License Agreement with University of Minnesota